Company Overview and News


Add DBV
to your dashboard

Headline News

8 Stocks That Will Hit All-Time Lows in 2018

2018-01-19 investorplace
Broad markets are at all-time highs, but not every stock has joined in the fun. Major industries such as energy and retail — even with the latter group posting a nice rally at the end of 2017 — are struggling. Outside those sectors, other companies have tumbled due to execution issues or competitive problems, making them stocks to sell in 2018. (623-8)

Aimmune Therapeutics - Desensitize Yourself For A Good Bet!

2017-12-20 seekingalpha
Have you ever noticed a disclaimer on packaging that states that a product was manufactured in a facility that also handles peanuts? Of course you have! Peanut allergies are terrifying to parents worldwide, peanut allergy is the most common form of food related death across the globe and currently the only treatment is a shot of epinephrine, turning parents into makeshift molecular biologists in attempting to keep their children away from anything related to the delicious legume. (5-1)

Aimmune Therapeutics: Upside Into Q1 Data And Beyond

2017-12-07 seekingalpha
We take a look at progress made since February and other bullish developments such as the trial failure of competitor DBV Technologies. (21-0)

Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies

2017-11-30 seekingalpha
DBV Technologies recently failed a pivotal Phase 3 trial, and as the old saying goes, “one man’s loss is another man’s gain.”. (17-0)

Update On Aimmune Therapeutics Vs. DBV Technologies Peanut Allergy-Related Candidate Treatments

2017-11-29 seekingalpha
AIMT gained about 40% of its value and appears close to fully valued for upcoming Phase 3 success. (5-1)

DBV Technologies to Attend Citi's 2017 Global Healthcare Conference

2017-11-28 marketwired
MONTROUGE, FRANCE--(Marketwired - November 28, 2017) - DBV Technologies (EURONEXT PARIS: DBV) (ISIN: FR0010417345) (NASDAQ: DBVT) today announced that David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Susanna Mesa, SVP, Strategy, will host investor meetings at Citi's 2017 Global Healthcare Conference in New York, NY on Wednesday, December 6, 2017.

Biotech Forum Daily Digest: What Now For Sarepta?

2017-11-21 seekingalpha
Biotech fell to begin the holiday shortened trading week, continuing a bout of poor performance in the fourth quarter of this year. (143-1)

Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview

2017-11-12 seekingalpha
With recent CAR-T approval, TC believes that the Kite Pharma Acquisition added significant value to Gilead Sciences. (242-12)

Insight From The Stellar Scientist Trader - An Integrated BioSci Investing Report

2017-10-25 seekingalpha
In the previous week, Dr. Tran BioSci of Integrated BioSci Investing had the honor to sit down with the expert, Decision Analytics in an interview. Our readers greatly benefited from his wisdom. His recommendation on Spectrum Pharmaceuticals (NASDAQ:SPPI) proved correct. The stock increased 36% the following day (and reached its 52-weeks high) after the accurate forecasting of the phase 2 trial (which studied poziotinib as a treatment for non small cell lung cancer with exon 20 mutation). (372-6)

Stock plunges for peanut allergy patch maker

2017-10-24 money.cnn
DBV Technologies (DBVT) revealed on Friday that late-stage clinical trials for its patch vaccine, Viaskin Peanut, missed the primary endpoint. That's the bar that typically means the difference between a marketable drug and one that isn't. The company's stock price plummeted more than 50% on Monday. (5-1)

Eldorado Gold, DBV Technologies Crash into Monday’s 52-Week Low Club

2017-10-23 247wallst
October 23, 2017: Here are four stocks trading with heavy volume among 79 equities making new 52-week lows in Monday’s session. On the NYSE, decliners led advancers by about 2 to 1 and on the Nasdaq decliners led advancers by a slightly larger ratio. (30-0)

Aimmune Soars On Rival Drug Flop For Peanut Allergy

2017-10-23 seekingalpha
The phase 3 PALISADE trial is expected to read out data in the coming months for patients with peanut allergies, providing a nice catalyst opportunity. (5-0)

Biotech Forum Daily Digest: Behind UniQure's Massive Rally

2017-10-23 seekingalpha
Sentiment on the biotech sector continues to be somewhat negative especially in the small cap part of this high beta part of the market. (210-1)

French Drugmaker Crashes After Peanut Allergy Treatment Fails a Major Trial - Bloomberg

2017-10-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (8-0)

Editors' Picks Daily: A Detailed Market Outlook, REITs And Buffett

2017-10-18 seekingalpha
Articles get tagged with an Editors’ Pick award when they appeal to a broad audience and demonstrate convincing analysis and a clear actionable takeaway. (5-0)